# Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

> **NCT06770764** · PHASE1 · RECRUITING · sponsor: **Trutino Biosciences Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** ODC-IL2

## Key facts

- **NCT ID:** NCT06770764
- **Lead sponsor:** Trutino Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770764, "Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06770764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*